Cargando…

Dissecting drivers of immune activation in chronic HIV-1 infection

BACKGROUND: Immune activation is a significant contributor to HIV pathogenesis and disease progression. In virally-suppressed individuals on ART, low-level immune activation has been linked to several non-infectious comorbid diseases. However, studies have not been systematically performed in sub-Sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Streeck, Hendrik, Maestri, Alvino, Habermann, Daniel, Crowell, Trevor A., Esber, Allahna L., Son, Gowoon, Eller, Leigh Anne, Eller, Michael A., Parikh, Ajay P., Horn, Peter A., Maganga, Lucas, Bahemana, Emmanuel, Adamu, Yakubu, Kiweewa, Francis, Maswai, Jonah, Owuoth, John, Robb, Merlin L., Michael, Nelson L., Polyak, Christina S., Hoffmann, Daniel, Ake, Julie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334338/
https://www.ncbi.nlm.nih.gov/pubmed/35905559
http://dx.doi.org/10.1016/j.ebiom.2022.104182
_version_ 1784759083033690112
author Streeck, Hendrik
Maestri, Alvino
Habermann, Daniel
Crowell, Trevor A.
Esber, Allahna L.
Son, Gowoon
Eller, Leigh Anne
Eller, Michael A.
Parikh, Ajay P.
Horn, Peter A.
Maganga, Lucas
Bahemana, Emmanuel
Adamu, Yakubu
Kiweewa, Francis
Maswai, Jonah
Owuoth, John
Robb, Merlin L.
Michael, Nelson L.
Polyak, Christina S.
Hoffmann, Daniel
Ake, Julie A.
author_facet Streeck, Hendrik
Maestri, Alvino
Habermann, Daniel
Crowell, Trevor A.
Esber, Allahna L.
Son, Gowoon
Eller, Leigh Anne
Eller, Michael A.
Parikh, Ajay P.
Horn, Peter A.
Maganga, Lucas
Bahemana, Emmanuel
Adamu, Yakubu
Kiweewa, Francis
Maswai, Jonah
Owuoth, John
Robb, Merlin L.
Michael, Nelson L.
Polyak, Christina S.
Hoffmann, Daniel
Ake, Julie A.
author_sort Streeck, Hendrik
collection PubMed
description BACKGROUND: Immune activation is a significant contributor to HIV pathogenesis and disease progression. In virally-suppressed individuals on ART, low-level immune activation has been linked to several non-infectious comorbid diseases. However, studies have not been systematically performed in sub-Saharan Africa and thus the impact of demographics, ART and regional endemic co-infections on immune activation is not known. We therefore comprehensively evaluated in a large multinational African cohort markers for immune activation and its distribution in various settings. METHODS: 2747 specimens from 2240 people living with HIV (PLWH) and 477 without HIV from the observational African Cohort Study (AFRICOS) were analyzed for 13 immune parameters. Samples were collected along with medical history, sociodemographic and comorbidity data at 12 HIV clinics across 5 programs in Uganda, Kenya, Tanzania and Nigeria. Data were analyzed with univariate and multivariate methods such as random forests and principal component analysis. FINDINGS: Immune activation was markedly different between PLWH with detectable viral loads, and individuals without HIV across sites. Among viremic PLWH, we found that all immune parameters were significantly correlated with viral load except for IFN-α. The overall inflammatory profile was distinct between men and women living with HIV, in individuals off ART and with HIV viremia. We observed stronger differences in the immune activation profile with increasing viremia. Using machine learning methods, we found that geographic differences contributed to unique inflammatory profiles. We also found that among PLWH, age and the presence of infectious and/or noninfectious comorbidities showed distinct inflammatory patterns, and biomarkers may be used to predict the presence of some comorbidities. INTERPRETATION: Our findings show that chronic immune activation in HIV-1 infection is influenced by HIV viral load, sex, age, region and ART use. These predictors, as well as associations among some biomarkers and coinfections, influence biomarkers associated with noncommunicable diseases. FUNDING: This work was supported by the President's Emergency Plan for AIDS Relief via a cooperative agreement between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense [W81XWH-11-2-0174, W81XWH-18-2-0040]. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70–25. This article was prepared while Michael A. Eller was employed at Henry M. Jackson Foundation for the Advancement of Military Medicine for the U.S. Military HIV Research Program. The views expressed are those of the authors and should not be construed to represent the positions of the US Army or the Department of Defense. The opinions expressed in this article are the author's own, and do not reflect the view of the National Institutes of Health, the U.S. Department of Health and Human Services, or the U.S. government.
format Online
Article
Text
id pubmed-9334338
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93343382022-07-30 Dissecting drivers of immune activation in chronic HIV-1 infection Streeck, Hendrik Maestri, Alvino Habermann, Daniel Crowell, Trevor A. Esber, Allahna L. Son, Gowoon Eller, Leigh Anne Eller, Michael A. Parikh, Ajay P. Horn, Peter A. Maganga, Lucas Bahemana, Emmanuel Adamu, Yakubu Kiweewa, Francis Maswai, Jonah Owuoth, John Robb, Merlin L. Michael, Nelson L. Polyak, Christina S. Hoffmann, Daniel Ake, Julie A. eBioMedicine Articles BACKGROUND: Immune activation is a significant contributor to HIV pathogenesis and disease progression. In virally-suppressed individuals on ART, low-level immune activation has been linked to several non-infectious comorbid diseases. However, studies have not been systematically performed in sub-Saharan Africa and thus the impact of demographics, ART and regional endemic co-infections on immune activation is not known. We therefore comprehensively evaluated in a large multinational African cohort markers for immune activation and its distribution in various settings. METHODS: 2747 specimens from 2240 people living with HIV (PLWH) and 477 without HIV from the observational African Cohort Study (AFRICOS) were analyzed for 13 immune parameters. Samples were collected along with medical history, sociodemographic and comorbidity data at 12 HIV clinics across 5 programs in Uganda, Kenya, Tanzania and Nigeria. Data were analyzed with univariate and multivariate methods such as random forests and principal component analysis. FINDINGS: Immune activation was markedly different between PLWH with detectable viral loads, and individuals without HIV across sites. Among viremic PLWH, we found that all immune parameters were significantly correlated with viral load except for IFN-α. The overall inflammatory profile was distinct between men and women living with HIV, in individuals off ART and with HIV viremia. We observed stronger differences in the immune activation profile with increasing viremia. Using machine learning methods, we found that geographic differences contributed to unique inflammatory profiles. We also found that among PLWH, age and the presence of infectious and/or noninfectious comorbidities showed distinct inflammatory patterns, and biomarkers may be used to predict the presence of some comorbidities. INTERPRETATION: Our findings show that chronic immune activation in HIV-1 infection is influenced by HIV viral load, sex, age, region and ART use. These predictors, as well as associations among some biomarkers and coinfections, influence biomarkers associated with noncommunicable diseases. FUNDING: This work was supported by the President's Emergency Plan for AIDS Relief via a cooperative agreement between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense [W81XWH-11-2-0174, W81XWH-18-2-0040]. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70–25. This article was prepared while Michael A. Eller was employed at Henry M. Jackson Foundation for the Advancement of Military Medicine for the U.S. Military HIV Research Program. The views expressed are those of the authors and should not be construed to represent the positions of the US Army or the Department of Defense. The opinions expressed in this article are the author's own, and do not reflect the view of the National Institutes of Health, the U.S. Department of Health and Human Services, or the U.S. government. Elsevier 2022-07-26 /pmc/articles/PMC9334338/ /pubmed/35905559 http://dx.doi.org/10.1016/j.ebiom.2022.104182 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Streeck, Hendrik
Maestri, Alvino
Habermann, Daniel
Crowell, Trevor A.
Esber, Allahna L.
Son, Gowoon
Eller, Leigh Anne
Eller, Michael A.
Parikh, Ajay P.
Horn, Peter A.
Maganga, Lucas
Bahemana, Emmanuel
Adamu, Yakubu
Kiweewa, Francis
Maswai, Jonah
Owuoth, John
Robb, Merlin L.
Michael, Nelson L.
Polyak, Christina S.
Hoffmann, Daniel
Ake, Julie A.
Dissecting drivers of immune activation in chronic HIV-1 infection
title Dissecting drivers of immune activation in chronic HIV-1 infection
title_full Dissecting drivers of immune activation in chronic HIV-1 infection
title_fullStr Dissecting drivers of immune activation in chronic HIV-1 infection
title_full_unstemmed Dissecting drivers of immune activation in chronic HIV-1 infection
title_short Dissecting drivers of immune activation in chronic HIV-1 infection
title_sort dissecting drivers of immune activation in chronic hiv-1 infection
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334338/
https://www.ncbi.nlm.nih.gov/pubmed/35905559
http://dx.doi.org/10.1016/j.ebiom.2022.104182
work_keys_str_mv AT streeckhendrik dissectingdriversofimmuneactivationinchronichiv1infection
AT maestrialvino dissectingdriversofimmuneactivationinchronichiv1infection
AT habermanndaniel dissectingdriversofimmuneactivationinchronichiv1infection
AT crowelltrevora dissectingdriversofimmuneactivationinchronichiv1infection
AT esberallahnal dissectingdriversofimmuneactivationinchronichiv1infection
AT songowoon dissectingdriversofimmuneactivationinchronichiv1infection
AT ellerleighanne dissectingdriversofimmuneactivationinchronichiv1infection
AT ellermichaela dissectingdriversofimmuneactivationinchronichiv1infection
AT parikhajayp dissectingdriversofimmuneactivationinchronichiv1infection
AT hornpetera dissectingdriversofimmuneactivationinchronichiv1infection
AT magangalucas dissectingdriversofimmuneactivationinchronichiv1infection
AT bahemanaemmanuel dissectingdriversofimmuneactivationinchronichiv1infection
AT adamuyakubu dissectingdriversofimmuneactivationinchronichiv1infection
AT kiweewafrancis dissectingdriversofimmuneactivationinchronichiv1infection
AT maswaijonah dissectingdriversofimmuneactivationinchronichiv1infection
AT owuothjohn dissectingdriversofimmuneactivationinchronichiv1infection
AT robbmerlinl dissectingdriversofimmuneactivationinchronichiv1infection
AT michaelnelsonl dissectingdriversofimmuneactivationinchronichiv1infection
AT polyakchristinas dissectingdriversofimmuneactivationinchronichiv1infection
AT hoffmanndaniel dissectingdriversofimmuneactivationinchronichiv1infection
AT akejuliea dissectingdriversofimmuneactivationinchronichiv1infection
AT dissectingdriversofimmuneactivationinchronichiv1infection